KYNTRA BIO INC.
KYNB evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Market Cap:
- $33.3M
- Lead Asset:
- EVRENZO (爱瑞卓®) / roxadustat (Approved)
What it means
What to watch
Prepared research question
What matters most for KYNB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · KYNB
KYNTRA BIO INC. (KYNB) is a biopharmaceutical company advancing a pipeline focused on oncology, including a Phase 2 CD46-targeted ADC for metastatic castration-resistant prostate cancer and a Phase 3 roxadustat program for anemia in lower-risk myelodysplastic syndromes, with a cash position extending into 2028.
Key risk: Negative shareholders' equity
BioSniper Score
Based on 5 of 6 signals
Market Cap
$33.3M
Cash Runway
—
Lead Asset
EVRENZO (爱瑞卓®) / roxadustat (Approved)
Next Catalyst
Phase3_Start · Apr 1, 2027Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 130 clinical trials · 1 catalyst for KYNTRA BIO INC..
KYNTRA BIO INC. (KYNB) is a biopharmaceutical company advancing a pipeline focused on oncology, including a Phase 2 CD46-targeted ADC for metastatic castration-resistant prostate cancer and a Phase 3 roxadustat program for anemia in lower-risk myelodysplastic syndromes, with a cash position extending into 2028.
- Cash & equivalents of $50.6M as of 2026-06-30 [sec].
- Net income of $12.0M for Q2 2026 [sec].
- Phase 2 monotherapy trial of FG-3246 (CD46-targeted ADC) in mCRPC continues enrolling with interim analysis on track for 4Q 2026 [news · 2026-08-13].
- Phase 3 protocol of roxadustat for anemia in LR-MDS with high transfusion burden finalized, with goal to initiate registrational study in 4Q 2026 [news · 2026-08-13].
- Shareholders' equity of -$30.1M as of 2026-06-30 [sec].
What works
- Cash position of $50.6M as of 2026-06-30 extends into 2028, providing a multi-year operational runway [sec].
- FG-3246 is a potential first-in-class ADC targeting CD46 in mCRPC, with an exclusive license and option to acquire Fortis Therapeutics by December 31, 2027 [pipeline].
- Roxadustat is already approved in some indications, and the company retains rights in the U.S., Canada, Mexico, and other markets, with Astellas holding rights in other regions [pipeline].
What to weigh
- Shareholders' equity is negative at -$30.1M as of 2026-06-30, indicating accumulated losses exceed equity [sec].
- The FG-3246 program is still in Phase 2, with no approved product in that indication, and the option to acquire Fortis would require an $80M payment plus up to $200M in milestones [pipeline].
- Roxadustat faces a competitive landscape including ESAs, luspatercept, and imetelstat for the MDS indication [pipeline].
From the filings
Quoted directly from source documents.
Phase 2 monotherapy trial of FG-3246 continues enrolling with interim analysis on track for 4Q 2026
“Phase 2 monotherapy trial of FG-3246, a potential first-in-class antibody drug conjugate (ADC) targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC), continues enrolling with interim analysis on track for 4Q 2026”
News · August 13, 2026
Phase 3 protocol of roxadustat for LR-MDS finalized, goal to initiate registrational study in 4Q 2026
“Phase 3 protocol of roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS) and high transfusion burden (HTB) has been finalized with the goal to initiate the registrational study in 4Q 2026”
News · August 13, 2026
Catalyst timeline
- 2027-04-01 · Phase3_Start — A Phase 3, randomized, double-blind, placebo-controlled study of roxadustat for anemia due to LR-MDS with high RBC transfusion burden is scheduled to start.
Risks & what to watch (3)›
Key risks
- Negative shareholders' equity — Shareholders' equity of -$30.1M as of 2026-06-30 indicates the company has more liabilities than assets [sec].
- FG-3246 acquisition cost — Option to acquire Fortis requires $80M payment plus up to $200M in milestones, a significant future cash commitment [pipeline].
- Competitive pressure on roxadustat — Roxadustat for MDS faces competitors including ESAs, luspatercept, and imetelstat [pipeline].
What to watch
- Interim analysis of FG-3246 Phase 2 trial in mCRPC expected in 4Q 2026 [news · 2026-08-13].
- Initiation of roxadustat Phase 3 registrational study for LR-MDS expected in 4Q 2026 [news · 2026-08-13].
- Decision on option to acquire Fortis Therapeutics by December 31, 2027 [pipeline].
- Cash runway extending into 2028 provides financial visibility but depends on spending discipline [news · 2026-08-17].
Sources: Catalysts · Competitor trials · News · Pipeline · Generated October 13, 2026 · How we verify sources →
Run KYNTRA BIO INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available KYNTRA BIO INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
Net income $12M
Lead: Approved
4 candidates
1 upcoming, next in ~169d
1 buy · 0 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
32
Total value held
$6.3M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 400,000 | $2.7M |
| vanguard capital management llc | 156,607 | $1.1M |
| blackrock, inc. | 84,331 | $572K |
| two sigma investments, lp | 49,511 | $336K |
| geode capital management, llc | 45,998 | $312K |
| hightower advisors, llc | 39,744 | $269K |
| ubs group ag | 27,591 | $187K |
| renaissance technologies llc | 27,481 | $186K |
| vanguard fiduciary trust co | 23,942 | $162K |
| birchview capital, lp | 22,566 | $153K |
Showing top 10 of 32 institutional holders of KYNTRA BIO INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 19, 2026- % of float
- 2.9%
- Days to cover
- 3.2
- Shares short
- 113,876
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
KYNB short interestGovernance
Frequently asked questions
What is the AI investment thesis for KYNTRA BIO INC.?
KYNTRA BIO INC. (KYNB) is a biopharmaceutical company advancing a pipeline focused on oncology, including a Phase 2 CD46-targeted ADC for metastatic castration-resistant prostate cancer and a Phase 3 roxadustat program for anemia in lower-risk myelodysplastic syndromes, with a cash position extending into 2028.
What is KYNTRA BIO INC.'s lead drug candidate?
KYNTRA BIO INC.'s most advanced tracked candidate is EVRENZO (爱瑞卓®) / roxadustat (Approved) for Myelodysplastic Syndromes.
What is KYNTRA BIO INC.'s next catalyst?
KYNTRA BIO INC.'s next tracked catalyst is a Phase3_Start event — "Phase3_Start: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) in Participants With High Red Blood Cell Transfusion Burden" — expected April 1, 2027.
Who is the CEO of KYNTRA BIO INC.?
Mr. Thane Wettig is the chief executive officer of KYNTRA BIO INC. (KYNB).
Where is KYNTRA BIO INC. headquartered?
KYNTRA BIO INC. (KYNB) is headquartered in San Francisco, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.